Compare AbbVie Inc (ABBV) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs PAGSEG Inc — how do they compare? AbbVie Inc trades at $253.45 (market cap $449.91B), while PAGSEG Inc trades at $8.74 (market cap $2.49B). The key difference: AbbVie Inc is far larger — about 180.7× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.69%). Which is the better fit depends on your goals.
| ABBV | PAGS | |
|---|---|---|
Market Cap | $449.91B | $2.49B |
Sector | Health | Technology |
52-Week High | $261.07 | $12.00 |
52-Week Low | $184.85 | $7.75 |
Enterprise Value | $513.38B | $10.12B |
Dividend Yield | 2.72% | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
PAGS trades at $8.93, down 2.08% for the day, with a bearish technical signal from moving averages. The stock shows strong value fundamentals with a P/E of 6.32 and P/B of 0.89. Recent earnings were mixed, missing in Q1 2026 but beating in Q4 2025. The company maintains solid profitability with a 10.4% net income margin and generated positive net cash flow of $930 million in 2025. A dividend of $0.26 per share is scheduled for payment on June 1, 2026.
The investment outlook is supported by deep valuation discounts and analyst optimism, with 15 buy ratings. However, near-term headwinds include flat payment volume growth and pressure from Brazilian interest rates. The primary risk remains macroeconomic sensitivity in Brazil, while the opportunity lies in potential expansion of banking and credit operations driving future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
